| 引用本文: | 王勉,胡静静,蔡兆斌.沙库巴曲缬沙坦在心血管疾病中的多效性研究进展[J].中国现代应用药学,2019,36(17):2236-2239. |
| WANG Mian,HU Jingjing,CAI Zhaobin.Advances Research of Sacubitril-valsartan's Pleiotropic Effects on Cardiovascular Diseases[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(17):2236-2239. |
|
| 摘要: |
| 沙库巴曲缬沙坦是全球首个血管紧张素受体脑啡肽酶抑制剂，它在拮抗血管紧张素Ⅱ受体的同时抑制脑啡肽酶的降解，大量临床试验资料表明它有潜力用于多种心血管疾病的治疗。熟悉沙库巴曲缬沙坦的临床应用，对更好地开发沙库巴曲缬沙坦具有深远意义。本文检索近年来国内外相关的文献报道，对沙库巴曲缬沙坦的药理作用及用于慢性射血分数降低的心力衰竭、慢性射血分数保留的心力衰竭的治疗以及其他方面如高血压、慢性肾功能不全、心肌梗死后的临床治疗及动物试验的相关进展进行综述。 |
| 关键词: 沙库巴曲缬沙坦 药理机制 心力衰竭 高血压 慢性肾功能不全 |
| DOI：10.13748/j.cnki.issn1007-7693.2019.17.024 |
| 分类号: |
| 基金项目: |
|
| Advances Research of Sacubitril-valsartan's Pleiotropic Effects on Cardiovascular Diseases |
|
WANG Mian1, HU Jingjing1, CAI Zhaobin2
|
|
1.Zhejiang Chinese Medical University, Hangzhou 310053, China;2.Xixi Hospital of Hangzhou, Hangzhou 310023, China
|
| Abstract: |
| Sacubitril-valsartan is the first-in-class angiotensin receptor-neprilysin inhibitor, with dual action mechanism that is antagonistic angiotensin Ⅱ receptor while inhibiting neprilysin. Datas from clinical studies of Sacubitril-valsartan suggest it has potential for the treatment of a variety of cardiovascular diseases. Familiar with the clinical application of Sacubitril-valsartan, has profound significance for the better development of it. According to the correlative reports in recent years, this paper reviewed it's pharmacologica mechanism and clinicalor animal trials of the heart failure with reduced ejection fraction and heart failure with preserved ejection fraction and other aspects such as hypertension, chronic renal impairment, and following myocardial infarction. |
| Key words: Sacubitril-valsartan pharmacological mechanism ejection fraction hypertension chronic renal impairment |
